We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Cytokines are cell-signaling proteins that orchestrate immune responses. While they play a pivotal role in regulating immune function, their clinical application as standalone therapeutics has been marred by significant limitations. Traditional cytokine therapies can trigger widespread immune activation, leading to off-target toxicities and limiting their efficacy. This inherent lack of specificity has underscored the need for innovative approaches that harness cytokine potential without unleashing indiscriminate immune responses.
One of the most promising aspects of cytokine-antibody fusion proteins is their potential to mitigate the widespread toxicity associated with traditional cytokine therapies. By delivering cytokine signals exclusively to target immune cells, the risk of systemic immune activation and consequent off-target damage is greatly minimized. This paradigm shift has profound implications for patient safety, enabling higher doses of cytokines to be used for enhanced therapeutic efficacy without compromising well-being.